We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the latest initiative to drive down drug costs, Sen. Byron Dorgan (D-N.D.) last week submitted a Canadian drug reimportation plan to HHS Secretary Tommy Thompson for approval as a two-year pilot project.
The merger of Dragon Pharmaceutical and Oriental Wave Holdings could lead to the first Chinese pharmaceutical firm being listed on Wall Street — evidence of the emergence of China as a major player in global drug development, industry analysts say.
Barr Pharmaceuticals and Galen Holdings have finalized agreements that give Barr exclusive rights to Galen’s Loestrin oral contraceptive products and Galen the option to market Barr’s generic version of its own oral contraceptive Ovcon 35.
Generic competition on selective serotonin reuptake inhibitor (SSRI) products during the next decade will significantly limit growth in the major depression drug market in the U.S., according to a new study by Decision Resources.
Ohio and Pennsylvania have joined a growing list of states suing brand and generic drugmakers for deceptive reporting of average wholesale price (AWP) data to inflate Medicare and Medicaid reimbursements for prescription drugs.
PhRMA has found an unlikely ally in its push to get the FDA to publish a final rule on paper pedigrees: consumer groups, who also have told the agency it should implement the final rule, but with a different objective in mind.
West Virginia lawmakers have overwhelmingly approved a bill that could force drug companies to set their prices at the lower rates established by federal or Canadian programs.
Saying the Bush administration has sold out to pharmaceutical manufacturers, Sen. John Kerry (D-Mass.) has embraced the reimportation of prescription drugs and negotiated drug prices under Medicare as part of his presidential campaign platform.
More than a week after receiving final FDA approval, generic firms Sandoz and Alphapharm have yet to launch their versions of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl).
Drugmakers with products in the lucrative antidepressant therapeutic class can expect to see their sales stall during the next decade as generic competition intensifies, according to a new study by Decision Resources.